{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T23:05:09Z","timestamp":1762643109916,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03058-7","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T08:57:30Z","timestamp":1734512250000},"page":"1009-1025","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2\u20134\u00a0Years with Rett Syndrome"],"prefix":"10.1007","volume":"42","author":[{"given":"Mona","family":"Darwish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Passarell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathie M.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"3058_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1651-2227.1985.tb10993.x","volume":"74","author":"B Hagberg","year":"1985","unstructured":"Hagberg B. Rett\u2019s syndrome: prevalence and impact on progressive severe mental retardation in girls. Acta Paediatr Scand. 1985;74:405\u20138.","journal-title":"Acta Paediatr Scand"},{"key":"3058_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13643-023-02169-6","volume":"12","author":"U Petriti","year":"2023","unstructured":"Petriti U, Dudman DC, Scosyrev E, Lopez-Leon S. Global prevalence of Rett syndrome: systematic review and meta-analysis. Syst Rev. 2023;12:5.","journal-title":"Syst Rev"},{"key":"3058_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1203\/PDR.0b013e3182242461","volume":"70","author":"S Fehr","year":"2011","unstructured":"Fehr S, Bebbington A, Nassar N, et al. Trends in the diagnosis of Rett syndrome in Australia. Pediatr Res. 2011;70:313\u20139.","journal-title":"Pediatr Res"},{"key":"3058_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ajmg.b.32707","volume":"180","author":"JL Neul","year":"2019","unstructured":"Neul JL, Benke TA, Marsh ED, et al. The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein\u00a02. Am J Med Genet B Neuropsychiatr Genet. 2019;180:55\u201367.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"3058_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/13810","volume":"23","author":"RE Amir","year":"1999","unstructured":"Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein\u00a02. Nat Genet. 1999;23:185\u20138.","journal-title":"Nat Genet"},{"key":"3058_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fncel.2014.00018","volume":"8","author":"G Baj","year":"2014","unstructured":"Baj G, Patrizio A, Montalbano A, Sciancalepore M, Tongiorgi E. Developmental and maintenance defects in Rett syndrome neurons identified by a new mouse staging system in vitro. Front Cell Neurosci. 2014;8:18.","journal-title":"Front Cell Neurosci"},{"key":"3058_CR7","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1093\/cercor\/bhv078","volume":"26","author":"F Bedogni","year":"2016","unstructured":"Bedogni F, Cobolli Gigli C, Pozzi D, et al. Defects during Mecp2 null embryonic cortex development precede the onset of overt neurological symptoms. Cereb Cortex. 2016;26:2517\u201329.","journal-title":"Cereb Cortex"},{"key":"3058_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/cne.22009","volume":"514","author":"PV Belichenko","year":"2009","unstructured":"Belichenko PV, Wright EE, Belichenko NP, et al. Widespread changes in dendritic and axonal morphology in Mecp2-mutant mouse models of Rett syndrome: evidence for disruption of neuronal networks. J Comp Neurol. 2009;514:240\u201358.","journal-title":"J Comp Neurol"},{"key":"3058_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/mrdd.10020","volume":"8","author":"B Hagberg","year":"2002","unstructured":"Hagberg B. Clinical manifestations and stages of Rett syndrome. Ment Retard Dev Disabil Res Rev. 2002;8:61\u20135.","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"3058_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13023-016-0499-7","volume":"11","author":"G Pini","year":"2016","unstructured":"Pini G, Bigoni S, Congiu L, et al. Rett syndrome: a wide clinical and autonomic picture. Orphanet J Rare Dis. 2016;11:132.","journal-title":"Orphanet J Rare Dis"},{"key":"3058_CR11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40265-023-01883-8","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ. Trofinetide: first approval. Drugs. 2023;83:819\u201324.","journal-title":"Drugs"},{"key":"3058_CR12","doi-asserted-by":"crossref","unstructured":"Hudu SA, Elmigdadi F, Qtaitat AA, et al. Trofinetide for Rett syndrome: highlights on the development and related inventions of the first USFDA-approved treatment for rare pediatric unmet medical need. J Clin Med. 2023;12:5114.","DOI":"10.3390\/jcm12155114"},{"key":"3058_CR13","doi-asserted-by":"publisher","first-page":"e1912","DOI":"10.1212\/WNL.0000000000007316","volume":"92","author":"DG Glaze","year":"2019","unstructured":"Glaze DG, Neul JL, Kaufmann WE, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019;92:e1912\u201325.","journal-title":"Neurology"},{"key":"3058_CR14","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41591-023-02398-1","volume":"29","author":"JL Neul","year":"2023","unstructured":"Neul JL, Percy AK, Benke TA, et al. Trofinetide for the treatment of Rett syndrome: a randomized phase\u00a03 study. Nat Med. 2023;29:1468\u201375.","journal-title":"Nat Med"},{"key":"3058_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40261-023-01322-2","volume":"44","author":"M Darwish","year":"2024","unstructured":"Darwish M, Nunez R, Youakim JM, Robertson P Jr. Characterization of the pharmacokinetics and mass balance of a single oral dose of trofinetide in healthy male subjects. Clin Drug Investig. 2024;44:21\u201333.","journal-title":"Clin Drug Investig"},{"key":"3058_CR16","unstructured":"Darwish M, Passarell J, Maxwell K, Youakim JM, Bradley H, Bishop KM. Weight-based banded dosing to achieve target exposure and exposure-response efficacy analyses to support trofinetide treatment in Rett syndrome. Presented at: American Society for Clinical Pharmacology and Therapeutics, March 22\u201324, 2023; Atlanta, GA, USA."},{"key":"3058_CR17","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1007\/s12325-024-02796-y","volume":"41","author":"M Darwish","year":"2024","unstructured":"Darwish M, Passarell J, Youakim JM, Bradley H, Bishop KM. Exposure-response efficacy modeling to support trofinetide dosing in individuals with Rett syndrome. Adv Ther. 2024;41:1462\u201380.","journal-title":"Adv Ther"},{"key":"3058_CR18","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/brain\/awy323","volume":"142","author":"A Banerjee","year":"2019","unstructured":"Banerjee A, Miller MT, Li K, Sur M, Kaufmann WE. Towards a better diagnosis and treatment of Rett syndrome: a model synaptic disorder. Brain. 2019;142:239\u201348.","journal-title":"Brain"},{"key":"3058_CR19","doi-asserted-by":"publisher","unstructured":"Percy A, Ryther R, Marsh E, et al. Trofinetide for the treatment of girls aged two to four years with rett syndrome: final results from the Open-label DAFFODIL Study (S37.003). Neurology. 2024;102(17_Suppl_1). https:\/\/doi.org\/10.1212\/WNL.0000000000204788.","DOI":"10.1212\/WNL.0000000000204788"},{"key":"3058_CR20","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40261-022-01156-4","volume":"42","author":"M Darwish","year":"2022","unstructured":"Darwish M, Youakim JM, Harlick J, DeKarske D, Stankovic S. A phase\u00a01, open-label study to evaluate the effects of food and evening dosing on the pharmacokinetics of oral trofinetide in healthy adult subjects. Clin Drug Investig. 2022;42:513\u201324.","journal-title":"Clin Drug Investig"},{"key":"3058_CR21","unstructured":"Darwish M, Youakim JM, DeKarske D, Stankovic S. A phase\u00a01, ascending-dose study to assess the potential effects of trofinetide on QTc interval, safety and tolerability, and pharmacokinetics in healthy adults [poster 212]. Presented at the 51st Child Neurology Society (CNS) Annual Meeting, October 12\u201315, 2022; Cincinnati, OH, USA."},{"key":"3058_CR22","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.2215\/CJN.01640309","volume":"4","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4:1832\u201343.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3058_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351.","journal-title":"AAPS J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03058-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03058-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03058-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T10:52:28Z","timestamp":1738407148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03058-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3058"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03058-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mona Darwish, Heather Bradley, and James M Youakim are employees of, and hold stock options in, Acadia Pharmaceuticals Inc. Kathie M Bishop is a consultant and former employee of Acadia Pharmaceuticals Inc. Julie Passarell and Kelly Maxwell, are employees of, and hold stock options in, Simulations Plus.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The clinical studies included in these analyses were conducted in accordance with Good Clinical Practice guidelines and the ethical principles of the Declaration of Helsinki. The study protocols were approved by the relevant institutional review boards or ethics committees at each study site, and parents\/guardians of study participants provided written informed consent prior to study entry.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}